Ikarian Capital, LLC Prothena Corp Public LTD CO Call Options Transaction History

Ikarian Capital, LLC

  • $573 Million
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$16.73 - $24.79 $197,414 - $292,522
11,800 New
11,800 $197,000
Q4 2023

Feb 14, 2024
BUY
$32.31 - $52.32 $19.4 Million - $31.4 Million
600,000 New
600,000 $21.8 Million
Q3 2022

Nov 14, 2022
BUY
$25.16 - $60.63 $1.68 Million - $4.05 Million
66,800 New
66,800 $4.05 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $678M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email